Information  X 
Enter a valid email address
  Print          More announcements

Wednesday 06 May, 2020

Morgan Stanley Cap

Rule 38.5 - ABBVIE INC.

RNS Number : 1232M
Morgan Stanley Capital Services LLC
06 May 2020
 

 

  FORM 38.5

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)

 

DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS

 

1.  KEY INFORMATION

 Name of exempt market-maker

  Morgan Stanley Capital Services LLC

 Company dealt in

  ABBVIE INC.

 Class of relevant security to which the dealings being disclosed relate (Note 1)

  US$0.01 COMMON STOCK

 Date of dealing

  05 MAY 2020

 

 

2.  DEALINGS  (Note 2)

 

(a)  Purchases and sales

 Total number of relevant secuities accquired

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

   227,410

 86.4300 USD

 82.7600 USD

 

 Total number of relevant secuities disposed

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

   13,274

 86.4200 USD

 82.0857 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

 Product name, e.g. CFD

 Nature of transaction

  (Note 4)

 Number of relevant securities

  (Note 5)

 Price per unit

 CFD

 LONG

 100

 84.6000 USD

 CFD

 LONG

 2,490

 85.0219 USD

 CFD

 LONG

 16

 85.0400 USD

 CFD

 LONG

 2,969

 85.5917 USD

 CFD

 LONG

 2,100

 86.1458 USD

 CFD

 LONG

 4,000

 86.1641 USD

 CFD

 SHORT

 11

 82.9200 USD

 CFD

 SHORT

 346

 84.3077 USD

 CFD

 SHORT

 142

 84.3078 USD

 CFD

 SHORT

 4,656

 84.3078 USD

 CFD

 SHORT

 34

 84.9298 USD

 CFD

 SHORT

 2,100

 85.3700 USD

 CFD

 SHORT

 1,245

 85.3700 USD

 CFD

 SHORT

 1,960

 85.3700 USD

 CFD

 SHORT

 160

 85.3700 USD

 CFD

 SHORT

 300

 85.4020 USD

 CFD

 SHORT

 400

 85.4020 USD

 CFD

 SHORT

 1,100

 85.4020 USD

 CFD

 SHORT

 900

 85.4020 USD

 CFD

 SHORT

 551

 85.5897 USD

 CFD

 SHORT

 37,496

 85.6674 USD

 CFD

 SHORT

 57,174

 85.6674 USD

 CFD

 SHORT

 11,748

 85.6674 USD

 CFD

 SHORT

 31,584

 85.6674 USD

 CFD

 SHORT

 969

 85.6674 USD

 CFD

 SHORT

 13,211

 85.6674 USD

 CFD

 SHORT

 8,696

 85.6674 USD

 CFD

 SHORT

 10,767

 85.6674 USD

 CFD

 SHORT

 2,673

 85.6674 USD

 CFD

 SHORT

 21,956

 85.6674 USD

 CFD

 SHORT

 3,721

 85.6674 USD

 CFD

 SHORT

 1,732

 85.6876 USD

 CFD

 SHORT

 11,100

 85.7670 USD

 CFD

 SHORT

 260

 86.0300 USD

 CFD

 SHORT

 79

 86.0399 USD

 CFD

 SHORT

 87

 86.1500 USD

 CFD

 SHORT

 124

 86.3800 USD

 

 

(c)  Options transactions in respect of existing relevant securities

 

i)  Writing, selling, purchasing or varying

 

 Product name, eg call option

 Writing, selling, purchasing, varying etc

 Number of securities to which the option relates (Note 5)

 Exercise Price

 Type, e.g American, European etc

 Expiry Date

 Option money paid/received per unit (Note 3)

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Product name, eg call option

 Number of securities

 Exercise price per unit (Note 3)

 N/A

 N/A

 N/A 

 

 

3. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 Date of disclosure

 06 MAY 2020

 Contact Name

Craig Horsley

 Telephone Number

+44(141) 245 7736

 Name of offeree/offeror with which connected

ABBVIE INC.

Nature of connection (Note 6)

Advisory

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEUNRRRRAUVRAR

a d v e r t i s e m e n t